Visceral Fat vs Subcutaneous Fat: Key Differences

Visceral fat vs subcutaneous fat is a distinction that matters far more to your health than the number on the scales. Both are types of body fat, but they differ fundamentally in where they sit, how they behave metabolically, and what risks they carry. Subcutaneous fat lies just beneath the skin and is the soft, pinchable layer most people are familiar with. Visceral fat sits deep within the abdominal cavity, surrounding vital organs. Understanding the difference can help you make sense of your cardiometabolic risk and take more targeted steps to protect your long-term health.

What is the difference between visceral fat and subcutaneous fat?

Subcutaneous fat lies beneath the skin and is pinchable, while visceral fat sits deep in the abdominal cavity surrounding organs. Visceral fat is more metabolically active and more strongly linked to cardiometabolic disease.

Visceral fat and subcutaneous fat are two distinct types of body fat that differ in location, structure, and metabolic behaviour. Subcutaneous fat sits directly beneath the skin and can be felt as the soft, pinchable layer around the abdomen, thighs, hips, and upper arms. Visceral fat, by contrast, lies deep within the abdominal cavity, surrounding internal organs such as the liver, pancreas, and intestines.^[12][13]

Both types of fat serve biological functions. Subcutaneous fat acts as an energy reserve, provides insulation, and cushions the body against physical impact. Visceral fat also stores energy, but because of its proximity to the portal circulation (the blood supply that drains directly into the liver), it behaves differently at a metabolic level and is more strongly associated with adverse cardiometabolic outcomes.

Both fat depots are metabolically active, but they differ in their adipokine profiles and their associations with health risk. Subcutaneous fat, particularly in the hips and thighs, can be relatively resistant to change and may have a degree of metabolic neutrality or even a modest protective effect in some contexts. Visceral fat is more strongly linked to insulin resistance, inflammation, and cardiometabolic disease, and tends to respond more readily to lifestyle interventions such as increased physical activity and dietary modification, though the degree of response varies by age, sex, genetics, and baseline fitness.

Fat distribution also changes across the life course. Hormonal shifts, including those associated with the menopause, can promote a redistribution of fat towards the visceral depot, which is one reason why cardiometabolic risk patterns differ between men and women at different life stages.^[7][8] Understanding this distinction matters because the health risks associated with each type of fat are not equivalent, and body weight or body mass index (BMI) alone does not distinguish between them.

Why is visceral fat considered more dangerous to your health?

Visceral fat drains into the portal vein, delivering fatty acids and pro-inflammatory cytokines directly to the liver, promoting insulin resistance, raised triglycerides, and chronic inflammation linked to cardiovascular disease and type 2 diabetes.

Visceral fat is considered more harmful than subcutaneous fat because of its direct metabolic and inflammatory effects. Because visceral fat drains into the portal vein, the fatty acids and bioactive molecules it releases travel directly to the liver, where they can promote insulin resistance, raise triglyceride levels, and contribute to metabolic dysfunction-associated steatotic liver disease (MASLD, formerly known as non-alcoholic fatty liver disease or NAFLD).^[5][12]

Visceral fat secretes a range of signalling molecules known as adipokines, including pro-inflammatory cytokines such as interleukin-6 (IL-6) and tumour necrosis factor-alpha (TNF-alpha).^[5][13] Elevated levels of these molecules are associated with chronic low-grade inflammation, which is a recognised driver of cardiovascular disease and type 2 diabetes.

Research has consistently shown that people with higher levels of visceral fat face greater cardiometabolic risk even when their overall body weight falls within a normal range. This pattern, sometimes described as a metabolically unhealthy normal weight (MUNW), highlights why BMI is an imperfect measure of health risk. Two individuals with identical BMI values can have very different distributions of visceral and subcutaneous fat, and therefore very different risk profiles.

Subcutaneous fat, while not entirely without risk in large quantities, does not carry the same degree of metabolic hazard. Research suggests that subcutaneous fat in the lower body (the gluteofemoral region) may have a degree of protective effect, acting as a buffer that sequesters fatty acids away from vital organs, though this effect is modest and does not offset the risks of overall excess adiposity.

How can you tell how much visceral fat you are carrying?

Waist circumference is the most practical clinical indicator: above 94 cm in men and 80 cm in women signals increased risk per NHS and NICE guidance. A waist-to-height ratio of 0.5 or above also indicates elevated cardiometabolic risk.

Waist circumference is the most practical and widely used clinical indicator of visceral fat accumulation. NHS Health Checks and NICE obesity assessment guidance use waist circumference alongside BMI to assess cardiometabolic risk. As a general guide, a waist circumference above 94 cm (approximately 37 inches) in men and above 80 cm (approximately 31.5 inches) in women is associated with increased health risk, with measurements above 102 cm in men and 88 cm in women indicating substantially higher risk. These thresholds are based on WHO guidance and are used in UK clinical practice.

For people of South Asian, Chinese, or Japanese ethnicity, lower cut-offs apply: a waist circumference above 90 cm in men and above 80 cm in women from these groups is considered to indicate increased risk, reflecting differences in body composition and cardiometabolic risk at equivalent waist sizes.^[2][16]

To measure your waist correctly, stand relaxed and find the midpoint between the bottom of your lowest rib and the top of your hip bone (iliac crest). Wrap a tape measure around this point, breathe out gently, and take the reading without pulling the tape tight.

NICE guidance also recommends waist-to-height ratio as a practical risk indicator for adults. A ratio of 0.5 or above (that is, a waist circumference more than half your height) suggests increased cardiometabolic risk and is a useful complement to waist circumference measurement.

Waist-to-hip ratio is another measure sometimes used to identify central adiposity. It is calculated by dividing the waist circumference by the hip circumference. The World Health Organization considers a ratio above 0.90 in men and above 0.85 in women to be elevated.

More precise measurement of visceral fat requires imaging. Computed tomography (CT) and magnetic resonance imaging (MRI) can quantify visceral fat volume accurately, but these are not used routinely in clinical practice due to cost and, in the case of CT, radiation exposure. Dual-energy X-ray absorptiometry (DEXA) scanning offers a lower-radiation alternative and is increasingly used in research settings. Some consumer body composition scales use bioelectrical impedance to estimate visceral fat; however, these vary considerably in accuracy and their readings should not be used as the basis for clinical decisions.

For most people, a combination of waist circumference measurement and a conversation with their GP provides a practical starting point. Your GP can arrange relevant blood tests, including blood pressure, HbA1c, and a lipid profile, and can refer you to appropriate services such as NHS Weight Management programmes or the NHS Diabetes Prevention Programme where relevant. Bolt Pharmacy is a GPhC-registered UK online pharmacy offering online weight-management consultations, with prescriber review and pharmacist support, where clinically appropriate options may be discussed.

Which health conditions are linked to excess visceral fat?

Excess visceral fat is associated with type 2 diabetes, cardiovascular disease, MASLD, obstructive sleep apnoea, certain cancers, PCOS, and emerging evidence links it to cognitive decline.

Excess visceral fat is linked to a range of serious long-term health conditions, with cardiovascular disease and type 2 diabetes among the most well-established associations. The chronic low-grade inflammation and insulin resistance promoted by visceral fat create conditions in which blood glucose regulation deteriorates, blood pressure rises, and lipid profiles become unfavourable, with higher triglycerides and lower levels of high-density lipoprotein (HDL) cholesterol.

This cluster of metabolic abnormalities is recognised clinically as metabolic syndrome. Diagnostic criteria, as defined by the International Diabetes Federation (IDF) and other international bodies, include central obesity alongside raised fasting glucose, elevated blood pressure, and dyslipidaemia.^[16] Central obesity is a key component of these criteria.

Beyond cardiovascular and metabolic disease, excess visceral fat is associated with:

• Metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD): Visceral fat contributes directly to hepatic fat accumulation, which can progress to metabolic dysfunction-associated steatohepatitis (MASH) and, in some cases, cirrhosis. NICE guideline NG49 covers the assessment and management of this condition.^[4]

• Obstructive sleep apnoea: Abdominal fat deposition can affect respiratory mechanics and upper airway patency during sleep. NICE and NHS guidance covers assessment and management of this condition.

• Certain cancers: Evidence from Cancer Research UK and the World Cancer Research Fund links central adiposity to increased risk of colorectal, endometrial, and postmenopausal breast cancer, among others.^[11]

• Polycystic ovary syndrome (PCOS): Visceral fat and insulin resistance are closely interrelated in PCOS, worsening hormonal imbalance.

• Cognitive decline: Emerging research suggests associations between visceral adiposity and increased risk of dementia, though the mechanisms are still being investigated and evidence continues to develop.^[14][15]

Reducing visceral fat through sustained lifestyle change, including regular aerobic exercise in line with the UK Chief Medical Officers' Physical Activity Guidelines, a balanced diet, and adequate sleep, can meaningfully reduce these risks. If lifestyle measures are insufficient, your GP can discuss whether additional clinical support, including referral to NHS Weight Management services or the NHS Diabetes Prevention Programme, is appropriate.

Scientific References

1. Why your waist size matters.
2. Overweight and obesity management: Identifying and assessing overweight, obesity and central adiposity (NG246).
3. Calculate your waist to height ratio.
4. Metabolic dysfunction-associated steatotic liver disease (MASLD): assessment and management (NG49).
5. Visceral fat adipokine secretion is associated with systemic inflammation.
6. Cardiometabolic Outcomes Among Adults With Abdominal Obesity.
7. Perimenopause and metabolic vulnerability: hormones, body composition and lifestyle changes.
8. The Impact of the Menopausal Transition on Body Composition and Abdominal Fat Redistribution.
9. Energy Metabolism Changes and Dysregulated Lipid Metabolism in Postmenopausal Women.
10. A Matter of Fat: Body Fat Distribution and Cardiometabolic Disease in Africa.
11. Crosstalk between visceral adipose tissue secretome and tumoral microenvironment in obesity-induced colorectal cancer.
12. Visceral Adiposity and Renal Health: From Pathophysiological Mechanisms to Novel Therapeutic Strategies.
13. Male Obesity and Cardiometabolic Risk: Inflammatory Mechanisms and Clinical Implications.
14. Adiposity and Cognitive Performance in Older Men and Women from the Study of Muscle, Mobility and Aging (SOMMA).
15. Microbiota-Gut-Brain Axis Mechanisms in Cognitive Impairment Associated with Central Obesity.
16. Harmonizing the metabolic syndrome: a joint interim statement (Alberti et al.).

Frequently Asked Questions